Lund, Sweden, 14:00 CET, 20 May 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has today held its annual general meeting. In the light of the ongoing corona pandemic and in order to minimize the spread of the disease, the general meeting was held only through postal voting, without the possibility to attend in person, in accordance with temporary legislation.
The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board, and granted discharge of liability to Board members, CEO and deputy CEO. In addition, the following main resolutions were passed.
Resolution on allocation of the company’s result
The annual general meeting resolved to allocate the company’s result in accordance with the Board’s proposal, entailing that no dividends are paid and that available total funds of SEK 1,224,563,092 are carried forward.
Election of and remuneration for Board members and auditor
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Håkan Björklund, Björn Odlander, Lars Lidgren, Tone Kvåle and Lennart Johansson as ordinary Board members. Lennart Johansson was re-elected as chairman of the Board.
Furthermore, the annual general meeting resolved that Board remuneration shall be paid with SEK 375,000 to the chairman of the Board and with SEK 200,000 to each of the other Board members who are not employed by the company. Remuneration for committee work shall be paid with SEK 125,000 to the chairman of the Audit Committee, with SEK 70,000 to each of the other members of the Audit Committee, with SEK 50,000 to the chairman of the Remuneration Committee and with SEK 25,000 to each of the other members of the Remuneration Committee.
The annual general meeting also resolved to re-elect Ernst & Young AB as the accounting firm and remuneration for the auditor shall be paid in accordance with invoiced amounts in accordance with customary charging standards. Ernst & Young AB has informed that Ola Larsmon will continue to be appointed as the responsible auditor.
Resolution on instruction and charter for the Nomination Committee
The annual general meeting resolved to adopt an instruction and charter for the Nomination Committee, in accordance with the Nomination Committee’s proposal. The instruction and charter for the Nomination Committee shall apply until further notice.
Resolution on amendment of the articles of association
In accordance with the Board’s proposal, the annual general meeting resolved to introduce a new article 10 in the articles of association in order to enable the company to use the alternatives specified by the Swedish Companies Act in relation to proxy collection and postal voting in connection with general meetings.
Resolution on implementation of a long-term incentive program for senior executives and certain key employees and hedging measures
The annual general meeting resolved in accordance with the proposal from the Board to implement a long-term incentive program for employees. LTI 2021 entails that the participants will invest in a predetermined number of shares in the company and subject to certain terms they will be entitled to receive shares free of charge, so called performance shares, at the end of 2023.
As hedging measures in order to secure the company’s delivery of performance shares to the participants in LTI 2021 and therewith associated costs, the annual general meeting resolved to authorize the Board of directors to secure the company’s delivery of performance shares through the alternative method, a share swap-agreement with a third party. To secure the company’s delivery of performance shares to the participants in LTI 2021 and therewith associated costs, the total maximum number of shares that LTI 2021 may be comprised of amounts to 728,000.
Resolution on implementation of a long-term incentive program for certain Board members and hedging measures
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to implement a long-term incentive program for certain Board members. Board LTI 2021 entails that the participants will invest in a predetermined number of shares in the company and subject to certain terms they will be entitled to receive shares free of charge, so called performance shares, at the end of 2023.
To ensure the company’s delivery of performance shares to participants in Board LTI 2021 and therewith associated costs, the annual general meeting resolved on hedging measures corresponding to those adopted for LTI 2021, as described above. To secure the company’s delivery of performance shares to the participants in Board LTI 2021 and therewith associated costs, the total maximum number of shares that Board LTI 2021 may be comprised of amounts to 148,000.
Lund on 20 May 2021
BONESUPPORT HOLDING AB (publ)
For more information contact:
BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
www.cordcom.se
This information was submitted for publication, through the agency of the contact persons set out above, at 14:00 CET on 20 May 2021.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.